Saturday 17 October 2026 Export TDOC’s income statement to Excel — free account

Teladoc Health, Inc.

TDOC Healthcare Health Information Services

Teladoc Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, down 1.54% from fiscal 2024. In the quarter to June 2026, revenue fell 3.95%, EPS fell 10.5%, free cash flow fell 27.1% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.

5.67 0.30 −5.03%

Follow TDOC

Alert me

Market cap: $1.1B
P/E: 0.0×
Fwd P/E: −7.7×
Dividend yield: —
F-score: 5/9
Altman Z: −6.66
Beneish M: −3.26
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.07

Total sells 2.07

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	—	—	—	—	—	—	—	—	—	—
Sell	—	5	1	—	5	1	—	9	3	—	7	1

Insider Ownership 0.36%

Capital & Financial Ratios $m

Market Cap 1,080.00

Revenue 2,489.48

Net Income (177.39)

Free Cash Flow 88.56

Net Debt 222.35

Current Ratio 0.83

Debt/Equity 0.76

P/E ratio 0.00

Fwd P/E (7.70)

P/S ratio 0.41

P/B ratio 0.78

Past 5Y EPS Growth —

This Y EPS Growth 24.44%

Next Y EPS Growth 26.77%

Next Y revenue growth (4.35%)

Next 5Y EPS Growth 20.86%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 2.32%

10-year low 10-year high

P/B against its own 10 years 8.99%

10-year low 10-year high

EV/Sales against its own 10 years 17.51%

10-year low 10-year high

EV/FCF against its own 10 years 28.72%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1,124	1,298	781	774
Receivables	217	214	193	221
Inventory	30	38	38	29
Other	—	—	—	—
	1,489	1,664	1,119	1,148

	2023	2024	2025	Q'26
Payables	44	33	48	37
ST’ Debt	—	551	—	997
Other	—	—	—	—
	421	942	405	1,382

Compound Annual Growth %

	10y	5y	3y
Sales	41.73%	18.26%	1.68%
Cash Flow	0.00%	0.00%	15.85%
Earnings	0.00%	0.00%	0.00%
Book Value	22.74%	(38.60%)	(15.64%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	614	607	—	—	—
’25	629	632	626	642	2,530
’24	646	642	641	640	2,570
’23	629	652	660	661	2,602
’22	565	592	611	638	2,407
’21	454	503	522	554	2,033
’20	181	241	289	383	1,094

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	10	65	—	—	—
’25	16	91	99	88	294
’24	9	89	110	86	294
’23	13	101	106	130	350
’22	(32)	92	63	66	189
’21	(18)	52	77	83	194
’20	(6)	36	32	(115)	(54)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(26)	23	—	—	—
’25	(16)	32	68	53	137
’24	(27)	61	79	56	170
’23	(76)	30	36	94	194
’22	(89)	5	(20)	(36)	(140)
’21	(42)	29	48	40	75
’20	(11)	26	15	(131)	(102)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.36)	(0.21)	—	—	—
’25	(0.53)	(0.19)	(0.28)	(0.14)	(1.14)
’24	(0.49)	(4.92)	(0.19)	(0.28)	(5.87)
’23	(0.42)	(0.40)	(0.35)	(0.17)	(1.34)
’22	(41.58)	(19.22)	(0.45)	(23.49)	(84.60)
’21	(1.31)	(0.86)	(0.53)	(0.07)	(2.73)
’20	(0.40)	(0.34)	(0.43)	(4.19)	(5.36)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	9.08	15.65	30.88	46.00	81.30	87.27	22.35	15.02	6.76	6.35	Analyst estimates 2026–2028 Powerpack
	High	20.80	37.90	89.05	86.30	253.00	308.00	95.71	34.36	22.54	15.21
People
People	Employees	670	1,231	2,000	2,400	4,400	5,100	5,600	5,600	5,500	5,600
	Revenue/emp, $m	0.18	0.19	0.21	0.23	0.25	0.40	0.43	0.46	0.47	0.45
Income, $m
Income, $m	Revenue	123	233	418	553	1,094	2,033	2,407	2,602	2,570	2,530
	Gross margin, %	74.04	73.58	69.20	66.66	64.27	68.01	69.09	70.80	70.76	69.50
	EBT	(74)	(107)	(97)	(109)	(576)	(385)	(13,663)	(220)	(994)	(236)
	EBT margin, %	(59.85)	(45.87)	(23.20)	(19.78)	(52.65)	(18.92)	(567.69)	(8.44)	(38.67)	(9.31)
	Net income	(74)	(107)	(97)	(99)	(485)	(429)	(13,660)	(220)	(1,001)	(200)
	Depreciation	16	40	55	70	123	281	13,671	349	1,173	448
Per share, $
Per share, $	Revenue	2.91	4.21	6.35	7.70	12.09	12.95	14.91	15.81	15.07	14.36
	Earnings	(1.75)	(1.93)	(1.47)	(1.38)	(5.36)	(2.73)	(84.60)	(1.34)	(5.87)	(1.14)
	Cash flow	(1.23)	(0.62)	(0.07)	0.42	(0.59)	1.24	1.17	2.13	1.72	1.67
	Capex	(0.11)	(0.15)	(0.11)	(0.25)	(0.53)	(0.76)	(2.04)	(0.95)	(0.73)	(0.89)
	Free cash flow	(1.34)	(0.77)	(0.18)	0.16	(1.12)	0.48	(0.87)	1.18	0.99	0.78
	Book value	5.45	10.08	15.39	14.11	175.49	102.24	14.29	14.13	8.74	7.86
	Shares, m	42	55	66	72	91	157	161	165	171	176
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	5.67	8.60	7.81	10.87	16.54	7.09	1.51	1.39	0.60	0.49
	P/B	3.03	3.59	3.22	5.93	1.14	0.90	1.58	1.55	1.04	0.89
	EV/Sales	5.50	8.97	7.66	10.74	17.12	7.26	1.78	1.55	0.70	0.79
	EV/FCF	(11.96)	(48.87)	(263.92)	513.27	(184.44)	197.61	(30.60)	111.48	29.98	14.55
Cash, $m
Cash, $m	Operating cash flow	(52)	(34)	(5)	30	(54)	194	189	350	294	294
	Capex	(5)	(8)	(7)	(18)	(48)	(119)	(329)	(156)	(124)	(157)
	Free cash flow	(57)	(43)	(12)	12	(102)	75	(140)	194	170	137
Balance, $m
Balance, $m	Working capital	62	116	470	498	727	894	916	1,068	722	714
	Total debt	44	207	415	445	1,422	1,239	1,549	1,539	1,542	995
	Net debt	(21)	85	(64)	(72)	636	343	631	415	244	214
	Shareholders’ equity	231	559	1,013	1,014	15,884	16,046	2,308	2,326	1,491	1,386
Returns, %
Returns, %	ROA	(27.83)	(18.93)	(8.25)	(6.31)	(5.01)	(2.42)	(123.73)	(5.04)	(25.32)	(6.28)
	ROIC	(18.70)	(7.32)	(4.67)	(5.34)	(1.92)	(1.01)	(290.36)	(5.67)	(36.78)	(10.27)
	ROE	(36.25)	(27.04)	(12.35)	(9.75)	(5.74)	(2.69)	(148.85)	(9.51)	(52.46)	(13.93)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
OMCL Omnicell, Inc.	$1.6B	41.6×	55.1×	+7.45% (above 0%: growing)	+341.67% (above 0%: growing)	+107.90% (above 0%: growing)	48.98%	10.39%	Compare
CERT Certara, Inc.	$1.5B	— (loss-making)	— (loss-making)	+0.99% (above 0%: growing)	n/m	−78.46% (below 0%: shrinking)	62.34%	(0.21%)	Compare
GDRX GoodRx Holdings, Inc.	$1.2B	62.7×	30.9×	−1.31% (below 0%: shrinking)	−25.00% (below 0%: shrinking)	+112.45% (above 0%: growing)	89.52%	11.79%	Compare
OMDA Omada Health, Inc.	$1.1B	252×	143×	+43.12% (above 0%: growing)	n/m	+45.71% (above 0%: growing)	72.62%	4.04%	Compare
TDOC Teladoc Health, Inc.	$1.1B	— (loss-making)	— (loss-making)	−3.95% (below 0%: shrinking)	n/m	−27.07% (below 0%: shrinking)	68.56%	(6.11%)
HSTM HealthStream, Inc.	$1.0B	46.0×	34.4×	+12.55% (above 0%: growing)	+27.78% (above 0%: growing)	+362.71% (above 0%: growing)	65.35%	9.94%	Compare
PHR Phreesia, Inc.	$685.3M	64.4×	23.5×	+10.41% (above 0%: growing)	+200.00% (above 0%: growing)	+43.51% (above 0%: growing)	66.64%	5.88%	Compare
MDRX Veradigm Inc.	$654.5M	— (loss-making)	— (loss-making)	−9.74% (below 0%: shrinking)	n/m	−66.33% (below 0%: shrinking)	50.53%	(37.41%)	Compare
SOPH SOPHiA GENETICS SA	$620.6M	— (loss-making)	— (loss-making)	+27.22% (above 0%: growing)	n/m	+6.50% (above 0%: growing)	64.61%	(86.03%)	Compare
Median of peers	$1.1B	62.7×	34.4×	+8.93%	+113.89%	+44.61%	64.98%	4.96%

All 51 Health Information Services stocks →

Teladoc Health, Inc. (TDOC) key facts

Concern: Teladoc Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, down 1.54% from fiscal 2024.
Teladoc Health, Inc. (TDOC) is a Health Information Services company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, TDOC traded at $5.67, a market capitalization of $1.1 billion.
Return on equity was −13.9% and debt-to-equity 0.76.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −6.66 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.